文献速递流行病学与生物统计临床试验与 GCP

生殖器疱疹的血清学筛查:美国预防服务工作组更新版证据报告与系统综述

Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2016-01-01

该系统综述评估无症状成人及青少年生殖器单纯疱疹病毒(HSV)血清学筛查及预防干预的证据,纳入17项研究共9736名参与者。最常用筛查试验在厂家界值下汇总灵敏度99%、特异度81%,在HSV-2患病率16%人群中阳性预测值仅50%。无随机对照试验比较筛查与不筛查,血清学筛查与心理社会伤害相关,预防性抗病毒药物的获益证据不一致。

要点

  • 无随机对照试验比较生殖器疱疹血清学筛查与不筛查的获益。
  • 最常用筛查试验在厂家界值下汇总灵敏度99%、特异度81%,假阳性率高。
  • 血清学筛查与心理社会伤害相关,包括阳性结果相关的痛苦和焦虑。

核心结论

  • 生殖器疱疹血清学筛查与高假阳性率及潜在心理社会伤害相关。
  • 随机对照试验证据未能确定无症状HSV-2感染的预防性抗病毒药物是否具有获益。

研究设计与样本

  • 该系统综述检索MEDLINE、Cochrane图书馆、EMBASE及试验注册库至2016年3月31日,并对目标出版物进行新证据监测至2016年10月31日。
  • 纳入17项研究(n=9736名参与者;范围24-3290),来自19篇出版物。

主要发现

  • 无随机对照试验比较筛查与不筛查。
  • 最常用筛查试验在厂家界值下汇总灵敏度99%(95%CI,97%-100%)、特异度81%(95%CI,68%-90%)(10项研究;n=6537)。
  • 在更高界值下,汇总灵敏度95%(95%CI,91%-97%)、特异度89%(95%CI,82%-93%)(7项研究;n=5516)。
  • 在HSV-2患病率16%的10万人口中使用该试验厂家界值,将产生15840例真阳性结果和15960例假阳性结果(阳性预测值50%)。
  • 4项随机对照试验比较预防性药物与安慰剂,2项在非妊娠无症状HSV-2血清阳性成人中,2项在HSV-2血清不一致夫妇中,两个人群结果异质且不一致。

关键数值与推荐

  • 最常用筛查试验厂家界值:汇总灵敏度99%(95%CI,97%-100%),汇总特异度81%(95%CI,68%-90%)(10项研究;n=6537)。
  • 更高界值:汇总灵敏度95%(95%CI,91%-97%),汇总特异度89%(95%CI,82%-93%)(7项研究;n=5516)。
  • HSV-2患病率16%的10万人口中,厂家界值下真阳性15840例、假阳性15960例,阳性预测值50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 无随机对照试验比较筛查与不筛查。
  • 大多数筛查试验准确性研究来自HSV-2高患病率人群(基于蛋白质印迹法大于40%)。
  • 预防性药物随机对照试验结果在两个人群中异质且不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Genital herpes simplex virus (HSV) infection is a prevalent sexually transmitted infection. Vertical transmission of HSV can lead to fetal morbidity and mortality. OBJECTIVE: To assess the evidence on serologic screening and preventive interventions for genital HSV infection in asymptomatic adults and adolescents to support the US Preventive Services Task Force for an updated recommendation statement. DATA SOURCES: MEDLINE, Cochrane Library, EMBASE, and trial registries through March 31, 2016. Surveillance for new evidence in targeted publications was conducted through October 31, 2016. STUDY SELECTION: English-language randomized clinical trials (RCTs) comparing screening with no screening in persons without past or current symptoms of genital herpes; studies evaluating accuracy and harms of serologic screening tests for HSV-2; RCTs assessing preventive interventions in asymptomatic persons seropositive for HSV-2. DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, and study quality; pooled sensitivities and specificities of screening tests using a hierarchical summary receiver operating characteristic curve analysis when at least 3 similar studies were available. MAIN OUTCOMES AND MEASURES: Accuracy of screening tests, benefits of screening, harms of screening, reduction in genital herpes outbreaks. RESULTS: A total of 17 studies (n = 9736 participants; range, 24-3290) in 19 publications were included. No RCTs compared screening with no screening. Most studies of the accuracy of screening tests were from populations with high HSV-2 prevalence (greater than 40% based on Western blot). Pooled estimates of sensitivity and specificity of the most commonly used test at the manufacturer's cutpoint were 99% (95% CI, 97%-100%) and 81% (95% CI, 68%-90%), respectively (10 studies; n = 6537). At higher cutpoints, pooled estimates were 95% (95% CI, 91%-97%) and 89% (95% CI, 82%-93%), respectively (7 studies; n = 5516). Use of this test at the manufacturer's cutpoint in a population of 100 000 with a prevalence of HSV-2 of 16% (the seroprevalence in US adults with unknown symptom status) would result in 15 840 true-positive results and 15 960 false-positive results (positive predictive value, 50%). Serologic screening for genital herpes was associated with psychosocial harms, including distress and anxiety related to positive test results. Four RCTs compared preventive medications with placebo, 2 in nonpregnant asymptomatic adults who were HSV-2 seropositive and 2 in HSV-2-serodiscordant couples. Results in both populations were heterogeneous and inconsistent. CONCLUSIONS AND RELEVANCE: Serologic screening for genital herpes is associated with a high rate of false-positive test results and potential psychosocial harms. Evidence from RCTs does not establish whether preventive antiviral medication for asymptomatic HSV-2 infection has benefit.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Feltner C, Grodensky C, Ebel C, et al. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016. PMID: 27997660. doi:10.1001/jama.2016.17138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。